Advertisement

Topics

Lannett Comments On FDA Proposal Regarding Methylphenidate Extended Release Tablets

03:03 EDT 19 Oct 2016 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
PHILADELPHIA, Oct. 19, 2016 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) received a notice from the U.S. Food and Drug Administration (FDA) that it will seek to withdraw approval of the Company's Abbreviated New Drug Application (ANDA) for Methyl...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Lannett Comments On FDA Proposal Regarding Methylphenidate Extended Release Tablets"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...